Pieris Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen S. Yoder
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 255 State Street Boston MA United States of America 02109
- IPO Date
- Jan 2, 2015
- CIK
- 0001583648
- Website
- pieris.com
- Similar Companies
- Business
- Pieris Pharmaceuticals, Inc. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) is a clinical-stage biotechnology company focused on developing Anticalin-based therapeutics targeting validated disease pathways in respiratory diseases and immuno-oncology. Founded in 2001 and headquartered in Boston, Massachusetts, with additional operations in Hallbergmoos, Germany, the company leverages its proprietary Anticalin platform to engineer protein-based drugs, including inhalable Anticalin proteins for moderate-to-severe asthma and multispecific Anticalins such as 4-1BB bispecifics for solid tumors. Its core products and services encompass PRS-060, an inhaled IL-4 receptor alpha antagonist partnered with AstraZeneca; PRS-343, a 4-1BB/HER2 bispecific; PRS-344, a 4-1BB/PD-L1 bispecific partnered with Servier; and other partnered immuno-oncology assets including SGN-BB228 with Pfizer (formerly Seagen) and BOS-342 with Boston Pharmaceuticals, which provide potential development, regulatory, and commercial milestones up to $275 million plus royalties in mid-single to low-double digits on net sales; as well as preclinical respiratory candidates like PRS-220 and PRS-400. Pieris serves pharmaceutical partners and patients in oncology and respiratory markets across North America, Europe, and select global regions through these collaborations. In recent developments, Pieris completed a merger with Palvella Therapeutics in December 2024, making Palvella a wholly-owned subsidiary advancing QTORIN rapamycin for rare genetic skin diseases including microcystic lymphatic malformations and cutaneous venous malformations, supported by an $80 million cash position extending into 2027; announced a strategic repositioning in March 2024 to maximize partnered milestone and royalty potential through cost reductions, workforce streamlining, R&D discontinuation, and pursuit of asset sales or monetization; and achieved a milestone in 2025 for Boston Pharmaceuticals' Phase 1/2 initiation of BOS-342.
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Best Penny Stocks To Buy Under $1.25? 3 To Watch Now
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for August 23rd
Penny Stocks To Buy This Week? 4 To Watch Under $5
Pieris (PIRS) Up On Receiving Milestone Payment From Partner